The Medical Letter on Drugs and Therapeutics
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB). It is the first drug approved specifically to treat MDR-TB.

ACTIVITY — Bedaquiline inhibits the proton pump of mycobacterial ATP synthase, the enzyme essential for energy production in Mycobacterium tuberculosis. In vitro, it is highly active against drug-sensitive and drug-resistant isolates of M. tuberculosis. In treatmentnaive patients with drug-sensitive tuberculosis, the bactericidal activity of bedaquiline administered as monotherapy for 7 days was similar to that of isoniazid or rifampin, but with a delayed onset.1 No cross-resistance with other TB drugs has ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
Article code: 1423b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian